Pleural Medicine Unit

One of the most active pleural research groups in the world, and uniquely combines a clinical and a laboratory arm closely integrated with the most active tertiary pleural services in Australasia.

ADAPT-1

SCGH Pleural Medicine Unit

1 minute

ADAPT-1

Intrapleural therapy with a combination of tissue plasminogen activator (tPA) 10mg and DNase 5mg administered twice daily has been shown to successfully manage over 90% patients with pleural infection without surgery. Our dose de-escalation series aim to establish the lowest effective dosing regimen for tPA/DNase. ADAPT-1 aims to evaluate the efficacy and safety of a reduced starting dose regimen of 5mg of tPA with 5mg of DNase administered intrapleurally twice daily in 61 patients.

93.4% of patients were successfully treated with 5mg tPA/5mg DNase without needing surgery. This provides the platform for further dose de-escalation studies.

Publication: J Thorac Dis.